FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 352:2640-2642 June 23, 2005 Number 25 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text PDF PDA Full Text Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited E-mail When Letters Appear Related Article by Winton, T. PubMed Citation

Lung cancer has been the most common cancer in the world since 1985 and is today the leading cause of cancer-related death. In 2002, there were 1.35 million new cases and 1.18 million related deaths worldwide.¹ Non–small-cell lung cancer, the most common form, accounts for 80 to 85 percent of cases. Given the size of the problem, the benefit of adjuvant chemotherapy for non–small-cell lung cancer, reported by Winton et al. in this issue of the Journal, has tremendous implications.²

Complete surgical resection is the best hope for cure in patients with operable non–small-cell lung cancer, yet the five-year overall . . . [Full Text of this Article]

Source Information

From the Department of Thoracic and Head and Neck Medical Oncology, University of Texas M.D. Anderson Cancer Center, Houston.

This article has been cited by other articles:

• Ost, D., Goldberg, J., Rolnitzky, L., Rom, W. N. (2008). Survival after Surgery in Stage IA and IB Non-Small Cell Lung Cancer. Am. J. Respir. Crit. Care Med. 177: 516-523 [Abstract] [Full Text]  
• Wind, J., Smit, E. J., Senan, S., Eerenberg, J.-P. (2007). Residual disease at the bronchial stump after curative resection for lung cancer. Eur. J. Cardiothorac. Surg. 32: 29-34 [Abstract] [Full Text]  
• Lee, B. E., von Haag, D., Lown, T., Lau, D., Calhoun, R., Follette, D. (2007). Advances in positron emission tomography technology have increased the need for surgical staging in non-small cell lung cancer. J. Thorac. Cardiovasc. Surg. 133: 746-752 [Abstract] [Full Text]  
• Seve, P., Lai, R., Ding, K., Winton, T., Butts, C., Mackey, J., Dumontet, C., Dabbagh, L., Aviel-Ronen, S., Seymour, L., Whitehead, M., Tsao, M.-S., Shepherd, F. A., Reiman, T. (2007). Class III {beta}-Tubulin Expression and Benefit from Adjuvant Cisplatin/Vinorelbine Chemotherapy in Operable Non-Small Cell Lung Cancer: Analysis of NCIC JBR.10. Clin. Cancer Res. 13: 994-999 [Abstract] [Full Text]  
• Johnson, D. H. (2006). Targeted therapies in combination with chemotherapy in non-small cell lung cancer.. Clin. Cancer Res. 12: 4451s-4457s [Abstract] [Full Text]  
• Rusch, V. W. (2005). Mediastinoscopy: An Endangered Species?. JCO 23: 8283-8285 [Full Text]